Stay updated on Tucatinib Combo in Advanced HER2+ Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Tucatinib Combo in Advanced HER2+ Breast Cancer Clinical Trial page.

Latest updates to the Tucatinib Combo in Advanced HER2+ Breast Cancer Clinical Trial page
- Check2 days agoChange DetectedPublications section now lists the NEJM article by Murthy et al. on tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer with full author names and citation details. The previous NEJM entry that included an erratum has been removed.SummaryDifference0.0%

- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedAdded a new revision label v3.5.3 and removed the previous v3.5.2, indicating an updated release version on the page. This appears to be a meta-level update rather than a change to study details or content.SummaryDifference0.0%

- Check32 days agoChange DetectedThe page’s displayed revision version was updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check39 days agoChange DetectedPublication reference in the Publications section was updated: the NEJM 2020 Tucatinib paper is added and the prior NEJM citation is removed.SummaryDifference0.0%

- Check60 days agoChange DetectedRevision tag updated from v3.4.3 to v3.5.0. No trial content or user-facing information was changed.SummaryDifference0.0%

- Check75 days agoChange DetectedRevision: v3.4.3 was added and Revision: v3.4.2 was removed.SummaryDifference0.0%

Stay in the know with updates to Tucatinib Combo in Advanced HER2+ Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tucatinib Combo in Advanced HER2+ Breast Cancer Clinical Trial page.